Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70868 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Gwaenaelle Aellen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology, University and Hospital Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Stenosis, Lithotripsy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Scientifique Cardiovasculaire, Fribourg.
Abstract (Originalsprache)
Background
Intravascular lithotripsy (IVL) has emerged as an effective technique for modifying heavily calcified coronary plaques, facilitating optimal stent expansion while minimizing procedural complications. However, data on periprocedural myocardial injury (PMI) and infarction (PPMI) following IVL remain scarce.
Aims
To evaluate the incidence of PMI and PPMI after IVL in an unselected real‐world population undergoing percutaneous coronary intervention (PCI).
Methods
All consecutive patients treated with IVL between May 2020 and December 2022 at a single tertiary center were included. Pre‐ and post‐procedural cardiac biomarkers (high‐sensitivity troponin T, CK, CK‐MB) and electrocardiograms were systematically analyzed. PMI and PPMI were defined according to the Fourth Universal Definition of Myocardial Infarction. A matched control cohort (2147 non‐IVL PCI patients) was used to compare biomarker dynamics.
Results
Among 90 patients (mean age 73 ± 9 years; 77% male), diameter stenosis decreased from 55.2% ± 15.5% before IVL to 40.3% ± 15.7% immediately after IVL, with a final residual stenosis of 5.5% ± 18.5% after PCI and increased median minimal lumen diameter from 1.22 [0.72–1.72] mm to 3.04 [2.64–3.57] mm. High‐sensitivity troponin and CK‐MB levels rose modestly following IVL‐assisted PCI ( p < 0.001), indicating mild myocardial injury. PMI was present in 49 patients (54%). Two patients met the criteria for PPMI, and no major procedural complication occurred. In an exploratory matched‐control analysis, IVL was associated with a moderate but statistically significant increase in biomarkers compared with matched controls (Cohen's d = 0.40).
Conclusion
In this single‐center observational study, IVL was associated with limited myocardial injury, while clinically overt PPMI remained uncommon. These findings support the favorable safety profile of IVL as a plaque‐modification strategy for complex calcified coronary lesions. ClinicalTrials.gov Identifier: NCT04185285.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology, University and Hospital Fribourg, Fribourg, Switzerland.
ORCID-Profile: Gwaenaelle Aellen, Dorian Garin, Yannick Faucherre, Mario Togni, Stéphane Cook
Förderung
- Fonds Scientifique Cardiovasculaire, Fribourg
Zitieren
APA
Aellen, G., Garin, D., Faucherre, Y., Puricel, S., Togni, M., & Cook, S. (2026). Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70868
Vancouver
Aellen G, Garin D, Faucherre Y, Puricel S, Togni M, Cook S. Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70868
BibTeX
@article{Aellen2026,
author = {Aellen, Gwaenaelle and Garin, Dorian and Faucherre, Yannick and Puricel, Serban and Togni, Mario and Cook, Stéphane},
title = {Incidence of Periprocedural Myocardial Injury and Infarction After Intravascular Lithotripsy for Calcified Coronary Artery Stenosis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70868}
}
EUVIMED